Skip to market wire
InvestLog
Back to Market返回行情

ATTO Attovia Therapeutics, Inc.

NASDAQHealthcare
$16.31-0.67%ClosedMarket Cap: $701.8M

As of 2026-10-08

Why ATTO matters now

Attovia Therapeutics, Inc. (ATTO) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.31 with -0.67% on the session and $701.8M in market capitalization.

The latest indexable market news headline is "Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026" from GlobeNewsWire.

Latest News

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026GlobeNewsWire · 2026-09-28
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · 2026-09-16
Attovia Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewsWire · 2026-09-03
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewsWire · 2026-09-02
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More247 Wallst · 2026-08-31

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

Beta

0.00

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.